Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppressor gene mutation in bilateral Wilms' tumor

Pathology International

Volumn 53, Issue 4, 2003, Pages 214-220

  Shibata, Rie ^a   Takata, Ayako ^a   Hashiguchi, Akinori ^a   Umezawa, Akihiro ^a   Yamada, Taketo ^a   Hata, Jun Ichi ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Chemotherapy; Fetal rhabdomyomatous nephroblastoma; Wilms' tumor; Wilms' tumor suppressor gene

Indexed keywords

DACTINOMYCIN; DNA; DOXORUBICIN; KI 67 ANTIGEN; MYOGENIN; PARAFFIN; PROTEIN S 100; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; LYMPHOCYTE; MALE; NEPHROBLASTOMA; POINT MUTATION; PRIORITY JOURNAL; SKELETAL MUSCLE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WT1 GENE;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENES, WILMS TUMOR; HUMANS; INFANT; KIDNEY NEOPLASMS; MALE; POINT MUTATION; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WILMS TUMOR; WT1 PROTEINS;

EID: 0038693403     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1320-5463.2003.01457.x     Document Type: Article

References (22)

1. Coppes MJ, Pritchard-Jones K. Principles of Wilms' tumor biology. Urol Clin North Am 2000; 27: 423-33.
2. Lee SB, Haber DA. Wilms' tumor and the WT1 gene. Exp Cell Res 2001; 264: 74-99.
3. Wigger HJ. Fetal rhabdomyomatous nephroblastoma-a variant of Wilms' tumor. Hum Pathol 1976; 7: 613-23.
4. Maes P, Delemarre J, de Kraker J, Ninane J. Fetal rhabdomyomatous nephroblastoma: a tumour of good prognosis but resistant to chemotherapy. Eur J Cancer 1999; 35: 1356-60.
5. Saba LM, de Camargo B, Gabriel-Arana M. Experience with six children with fetal rhabdomyomatous nephroblastoma: review of the clinical, biologic, and pathologic features. Med Pediatr Oncol 1998; 30: 152-5.
6. Call KM, Glaser T, Ito CY et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-20.
7. Gessler M, Poustka A, Cavenee W et al. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774-8.
8. Schumacher V, Schneider S, Figge A et al. Correlation of germline mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci USA 1997; 94: 3972-7.
9. Huff V, Miwa H, Haber DA et al. Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. Am J Hum Genet 1991; 48: 997-1003.
10. Knudson AG Jr, Strong LC. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst 1972; 48: 313-24.
11. Committee on histological classification of chirdhood tumors the Japanese pathological society. Histological classification and atlas of tumors in infancy and childhood I T Tumors of the urinary system. In: Urano Y, ed. Tumors of the Kidneys. Tokyo: Kanehara, 1988; 12-3.
12. Takata A, Kikuchi H, Fukuzawa R, Ito S, Honda M, Hata J. Constitutional WT1 correlate with clinical features in children with progressive nephropathy. J Med Genet 2000; 37: 698-701.
13. Little M, Holmes G, Bickmore W, van Heyningen V, Hastie N, Wainwright B. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet 1995; 4: 351-8.
14. Little M, Wells C. A crinical overview of WT1 gene mutations. Hum Mutat 1997; 9: 209-25.
15. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 1996; 87: 2171-9.
16. Kohler B, Schumacher V, I'Allemand D, Royer-Pokora B, Grutters A. Germline Wilms tumor suppressor gene (WT1) mutation leading to isolated genital malformation without Wilms tumor or nephropathy. J Pediatr 2001; 138: 421-4.
17. Miyagawa K, Kent J, Moore A et al. Loss of WT1 function leads to ectopic myogenesis in Wilms' tumour. Nat Genet 1998; 18: 15-7.
18. Anderson J, Slater O, McHigh K, Duffy P, Pritchard J. Response without shrinkage in bilateral Wilms tumors: Significance of rhabdomyomatous histology. J Pediatr Hematol Oncol 2002; 24: 31-4.
19. Nagashima Y, Nishihira H, Miyagi Y et al. A nude mouse Wilms' tumor line (KCMC-WT-1) derived from an aniridia patient with monoalleleic partial deletion of chromosome 11p. Cancer 1996; 77: 799-804.
20. Zuppan CW, Beckwith JB, Weeks DA, Luckey DW, Pringle KC. The effect of preoperative therapy on the histologic features of Wilms' tumor. An analysis of cases from the Third National Wilms' Tumor Study. Cancer 1991; 68: 385-94.
21. Seemayer TA, Harper JL, Shickelr D et al. Cytodifferentiation of a Wilms' tumor pulmonary metastasis: theoretic and clinical implications. Cancer 1997; 79: 1629-34.
22. Ishikawa K, Toyoda Y, Fukuzato Y, Kato K, Ijiri R, Tanaka Y. Maturation in the primary and metastatic resions of fetal rhabdomyomatous nephroblastoma. Med Pediatr Oncol 2001; 37: 62-3.